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Abstract
Introduction: Colorectal cancer (CRC) is one of the world’s three most common cancers and its incidence is rising. To
identify patients who benefit from adjuvant therapy requires novel biomarkers. The regenerating islet-derived gene (REG) 4
belongs to a group of small secretory proteins involved in cell proliferation and regeneration. Its up-regulated expression
occurs in inflammatory bowel diseases also in gastrointestinal cancers. Reports on the association of REG4 expression with
CRC prognosis have been mixed. Our aim was to investigate tumor REG4 expression in CRC patients and its coexpression
with other intestinal markers.
Methods: Tumor expression of REG4 was evaluated by immunohistochemistry in 840 consecutive surgically treated CRC
patients at Helsinki University Central Hospital. Expression of MUC1, MUC2, MUC5AC, synapthophysin, and chromogranin
was evaluated in a subgroup of 220 consecutively operated CRC patients. REG4 expression with clinicopathological
parameters, other intestinal markers, and the impact of REG4 expression on survival were assessed.
Results: REG4 expression associated with favorable clinicopathological parameters and with higher overall survival from
non-mucinous CRC (p = 0.019). For such patients under 65, its expression was an independent marker of lower risk of death
within 5 years that cancer; univariable hazard ratio (HR) = 0.57; 95% confidence interval (CI) (0.34–0.94); multivariable
HR= 0.55; 95% CI (0.33–0.92). In non-mucinous CRC, REG4 associated with positive MUC2, MUC4, and MUC5AC expression.
Conclusion: We show, to our knowledge for the first time, that REG4 IHC expression to be an independent marker of
favorable prognosis in non-mucinous CRC. Our results contradict those from studies based on quantification of REG4 mRNA
levels, a discrepancy warranting further studies.
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Introduction
The world’s third most common cancer, with an annual
incidence of over one million new cases, is colorectal cancer (CRC)
[1]. Its cure is based on early diagnosis, radical surgery, and
possible adjuvant therapy. Such therapy is routine for stage III
patients. At stage II, the advantage of adjuvant therapy is, however
unclear, since about 80% of surgically treated stage II patients
survive without chemotherapy. Although we know many high risk
factors; T4-stage, low differentiation, vascular invasion, tumor
obstruction, bowel perforation, and inadequate lymph node
resection, we cannot always identify patients who will benefit
from adjuvant therapy. It would be beneficial to find new
biomarkers to aid in treatment decisions.
Regenerating islet-derived gene (REG) proteins represent a
group of small secretory proteins involved in cell proliferation and
regeneration, that also participate in formation of the immune
system [2,3]. They belong to the calcium-dependent lectin (C-
lectin) superfamily and are divided into four families, REG I to IV,
based on their primary structure. At variance with the other REG
proteins, REG4 binds polysaccharides independently of calcium
[4]. The genes encoding REG I to III genes are located on
chromosome 2p12, while that of REG4 is on 1p12–13. REG4 was
first cloned and identified by Hartupee et al [5] and by
Ka¨ma¨ra¨inen et al [6]. Containing 158 aminoacids and with a
molecular of weight of 18 kDA, it is physiologically expressed in
the colon and the small intestine, with high expression in
enteroendocrine cells. [6,7]. In the gastrointestinal epithelium,
REG4 is activated during specific phases of differentiation and
maturation, its expression is spatially specific, and it has been
suggested to support mucinous and neuroendocrine differentiation
or [8,9]. Up-regulated REG4 expression occurs in inflammatory
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bowel diseases (IBD) [6] and also occurs in many malignancies:
colorectal, gastric, and pancreatic cancers [10–12]. REG4 is
suggested to participate in carcinogenesis and tissue regeneration,
to act as an antiapoptotic factor, and to promote proliferation and
invasion [13]. The ultimate physiological and pathological roles of
REG4 still remain elusive, however. Expression of REG4 in GI-
tract cancers has in several studies appeared to be of predictive
and prognostic value [10,11,14,15]. The findings in CRC have,
though, been controversial: increased expression is a sign of poor
prognosis according to Numata et al [16], but no association with
prognosis has emerged in other studies [17,18].
This study aimed to evaluate in CRC the role of REG4 as a
prognostic marker and its association with clinicopathological
parameters in a cohort of 840 patients. Furthermore, in a
subgroup of 220 patients, we focused on association of REG4
expression with other markers: markers of mucinous differentia-
tion MUC1, MUC2, MUC4, and MUC5AC, and also markers of
neuroendocrine phenotype: synaptophysin and chromogranin.
Methods
Patients
The study population comprised 840 consecutive colorectal
cancer patients undergoing surgery in 1983–2001 at the Depart-
ment of Surgery, Helsinki University Central Hospital. A
subgroup of 240 comprised consecutively operated patients
between 1998–2001. REG4 was studied in the whole patient
series, and the other markers studied in the subgroup. The Finnish
Population Register Centre provided the follow-up vital-status
data needed to compute survival statistics, and Statistics Finland
provided cause of death for all those deceased. Median age at
diagnosis was 66, with a median follow-up of 5.1 years (range 0–
25.8). The 5-year disease-specific survival rate was 58.9% (95% Cl
55.0–62.8%). For the subgroup, median age at diagnosis was 67
with a median follow-up of 6.0 years (range 0–13.2). The 5-year
disease-specific survival rate was 64.8% (95% Cl 58.1–71.5%).
Clinicopathological characteristics of both groups are in S1.
This study complies with the Declaration of Helsinki and was
approved by the Surgical Ethics Committee of Helsinki University
Central Hospital (Dnro HUS 226/E6/06, extension TMK02 166
17.4.2013) and the National Supervisory Authority of Welfare and
Health gave the permission to use tissue samples without
individual informed consent in this retrospective study (Valvira
Dnro 10041/06.01.03.01/2012).
Tissue microarray
Formalin-fixed and paraffin-embedded tumor samples came
from the archives of the Department of Pathology, Helsinki
University Central Hospital. Representative areas of tumor
samples on hematoxylin- and eosin-stained slides were marked
by an experienced pathologist. Three 1.0-mm-diameter punches
taken from each sample were mounted on each recipient paraffin
block with a semiautomatic tissue microarray instrument (TMA)
(Beecher Instruments, Silver Spring, MD) as described [19].
Immunohistochemistry
TMA- and tissue-blocks were freshly cut into 4-mm sections.
After deparaffinization in xylene and rehydration through a
gradually decreasing concentration of ethanol to distilled water,
the slides were treated in a PreTreatment module (Lab Vision
Corp., Fremont, CA) in pre-treatment buffer for 20 minutes at
98uC for antigen retrieval. The staining procedure by the Dako
REAL EnVision Detection system, Peroxidase/DAB+, Rabbit/
Mouse (Dako, Glostrup, Denmark) used an Autostainer 480 (Lab
Vision). Tissues were incubated with primary antibodies for one
hour at room temperature. The REG4 antibody is as described in
[20], others were from commercial sources. Antibodies and their
dilutions are in Table 1.
Scoring of samples
REG4 cytoplasmic expression was scored in tumor cells as
either negative of positive. MUC1 and MUC2 expressions were
cytoplasmic in tumor cells and were scored as negative-low-
moderate-high according to intensity. For further statistical
analysis they were grouped into: low (negative to low) and high
(moderate to high). MUC4 and MUC5AC cytoplasmic expres-
sions were scored either negative or positive. Neuroendocrinic
differentiation (negative vs positive) was evaluated by cytoplasmic
Figure 1. Immunohistochemical staining patterns of the antibiodies studied. Representative images of antibody stainings in colorectal
cancer; REG4-negative and -positive (A & B), MUC1- negative and -positive (C & D); MUC2-negative and -positive (E & F), MUC4-negative and -positive
(G & H), MUC5AC-negative and -positive (I & J), synapthophysin-negative and -positive (K & L), chromogranin-negative and -positive (M & N) Original
magnification was x 20.
doi:10.1371/journal.pone.0109600.g001
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synapthophysin and chromogranin positivity. Stainings were
scored independently by T.K. and J.H., who were blinded to
clinical data and outcome. Differences in scoring were discussed
until consensus. Representative images of expression are in
Figure 1. REG4 expression was compared with proliferation
index by Ki-67 staining, which we published previously [21].
Statistical analyses
Evaluation of the association between REG4 expression and
clinicopathological parameters or MUC expressions was done by
the exact Pearson chi-square test or the exact linear-by-linear
association test for ordered parameters. Disease-specific overall
survival was counted from date of surgery to date of death from
colorectal cancer, or until end of follow-up. Survival analysis by
the Kaplan-Meier method was compared by the log rank test. The
Cox regression proportional hazard model served for uni- and
multivariable survival analysis, adjusted for sex, age, Dukes
classification, and differentiation. Testing of the Cox model
assumption of constant hazard ratios over time involved the
inclusion of a time-dependent covariate separately for each
testable variable. The hazard ratio of differentiation was analyzed
in two periods (0 to 1.25 and 1.25 to 5 years) in order to meet the
assumptions of the Cox model, with the time-dependent Cox
model. Interaction terms were considered and an interaction
between REG4 expression and age emerged. We therefore
calculated the prognostic role of REG4 separately for patients
under and over 65. All tests were two-sided. A p-value of 0.05 was
considered significant. All statistical analyses were done with SPSS




REG4 expression in tumor cells was cytoplasmic and slightly
granular. When present, expression was evident in the vast
majority of tumor cells, but with no nuclear expression. In whole
tissue sections, no clear distinction in expression appeared between
the invasive front and the rest of the tumor. Moreover, in whole
sections, REG4 expression appeared in some cases in normal
epithelium, but was down-regulated in tumor cells. Expression of
mucins, synapthopysin, and chromogranin was cytoplasmic, with
no nuclear expression.
Of the 840 tumors represented in the TMA, REG4 staining
could be evaluated in 793; 580 (73.1%) were scored as negative
and 213 (28.9%) scored as positive. In a subgroup of 220 tumors,
MUC 1 expression was evaluated in 206 (low 83.5% and high
17.5%), MUC2 expression in 210 (low 17.1% and high 82.9%),
MUC4 expression in 208 (negative 51.0% and positive 49.0%),
and MUC5AC expression in 205 (negative 93.2% and positive
6.8%). Neuroendocrinic positivity (either/both synaptohysin- and
chromogranin-positive) could be evaluated in 212 (negative 92.9%
and positive 7.1%).
REG4 in lymph-node metastasis
Based on TMA results, we chose 10 patients with Dukes C
disease, 5 with REG4-positive tumors and 5 with negative tumors.
None of the patients’ REG4 negative tumors showed positivity in
their lymph-node metastasis, whereas of the 5 patients with
REG4-positive tumor, 2 showed positivity also in their lymph node
metastasis (Figure 2).
REG4 and clinicopathological parameters
Cytoplasmic REG4 expression associated with less-advanced
stage (p = 0.014), location in the right hemicolon (p= 0.035), and
mucinous histology (p,0.0001). We saw no association with age,
gender, differentiation, or location (colon vs. rectum) (Table 2). As
REG4 associated strongly with tumor histology, we analyzed
mucinous and non-mucinous CRC separately. In non-mucinous
CRC, REG4 expression associated with less advanced stage
(p = 0.005) and higher differentiaton (p = 0.023). No association
appeared with age, gender, tumor location, nor tumor side.
(Table 3) In mucinous CRC, REG4 expression did not associate
with any clinocopathological parameter (data not shown). No
association between REG4 and Ki-67 was seen in CRC nor in any
of the subgroups analyzed (data not shown).
REG4 and other intestinal markers
In the subgroup of 220 tumors, we found that REG4 expression
significantly associated with higher expression of MUC2, MUC4,
and MUC5AC, but not with MUC1 expression. Nor did REG4
expression associate with markers of neuroendocrine differentia-
tion. The same remained true when non-mucinous CRC was
analyzed alone (Table 4). In mucinous CRC, REG4 expression
associated with no other markers studied (data not shown).
Survival analysis
In non-mucinous, CRC REG4 positivity was a sign of favorable
prognosis (p = 0.019, log-rank test); 5-year DSS for patients with
positive cytoplasmic REG4 tumor expression was 67.9% (95% CI
60.5–75.3) compared to 57.8% (95% CI 53.5–62.1) for those with
no cytoplasmic expression (Figure 3). In mucinous CRC, no
difference appeared (data not shown). When we stratified non-
mucinous CRC for patients under or over 65, REG4 expression
was a sign of favorable prognosis in patients under 65 (p = 0.049,
Table 1. Antibodies for immunohistochemistry.
Antibody Clone Company Pre-treatment Dilution Positive control
REG4 mAb In-house Tris-HCl (pH 8.5) 1:50 Colon
MUC1 mAb, Ma552 Novocastra, UK Citrate (pH 6.0) 1:25 Stomach
MUC2 mAb, Ccp58 Novocastra, UK Citrate (pH 6.0) 1:100 Colon
MUC4 mAb, 1G8 Invitrogen,USA Tris-EDTA (pH 9.0) 1:100 Colon
MU5AC mAb, CLH2 Novocastra, UK Citrate (pH 6) 1:50 Stomach
Synaptophysin mAb 27G12 Novocastra, UK Tris-EDTA (pH 9.0) 1:200 Colon
Chromogranin mAb, 5H7 Novocastra, UK Tris-EDTA (pH 9.0) 1:2000 Colon
REG4 antibody described in detail in reference [20] mAb=monoclonal antibody. Antibody host: mouse.
doi:10.1371/journal.pone.0109600.t001
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log-rank test.), with no difference for those older (p = 0.195, log-
rank-test). (S2 & S3).
Cox regression univariable analyses confirmed these results,
with REG4 expression being a sign of a reduced risk of death
within 5 years for non-mucinous CRC. A significant difference
emerged also for patients under 65 (HR 0.57, 95% CI 0.34–0.94,
p = 0.029) but not for those older (HR 0.83, 95% CI 0.57–1.22,
p = 0.34). Cox regression multivariable analysis for non-mucinous
CRC patients under 65, adjusted for gender, stage, and
differentiation, showed that REG4 was an independent factor of
favorable prognosis (HR 0.55, 95% CI 0.33–0.92, p= 0.022)
(Table 5).
Discussion
Here we show by immunohistochemistry that REG4 expression
in non-mucinous colorectal cancer associates with favorable
clinicopathological parameters and that REG4 is an independent
marker of favorable prognosis in patients under 65. REG4
expression associates with expression of other intestinal markers:
MUC1, MUC2, and MUC5AC.
REG4 expression was higher in low-stage tumors and in those
with of mucinous histology. With mucinous tumors excluded,
REG4 expression associated significantly with higher differentia-
tion and low stage. REG4 expression also associated with MUC1,
MUC2, and MUC5AC, which supports the finding that REG4-
positive tumors are more highly differentiated than are those that
are REG4 negative. These results are in accordance with findings
of Li et al [17], who showed in that for REG4, immunohisto-
chemical (IHC) expression in CRC associates significantly with
higher differentiation and with absence of venous invasion.
Moreover, REG4 expression showed a trend like association with
low T-stage, absence of lymph node metastasis, and local disease
(Dukes A-B vs C-D). Similar results appear for gallbladder cancer,
where positive REG4 IHC expression, associates with higher
tumor differention [22]. Controversial results for CRC in Numata
et al. show that higher REG4 mRNA expression associates with
higher differentiation, deeper invasion (T-stage), lymphatic inva-
sion, presence of liver metastasis, and more advanced stage [16].
They, however measured mRNA levels by PCR, not as we did
actual protein expression.
Association between REG4 levels and carcinoma has been
under study in both serum and tissues. Elevated serum concen-
tration of REG4 in carcinoma patients compared to those in
healthy controls has been a finding in pancreatic cancer [12],
gastric cancer [11] and gallbladder cancer [22], indicating that
serum REG4 could serve as a diagnostic biomarker. Increased
REG4 IHC expression has been suggested as a marker of poor
prognosis in gastric cancer [23], and elevated tissue levels of REG4
mRNA may be a marker of poor prognosis in CRC [16]. REG4
IHC expression has shown, however, no effect on prognosis in
CRC [17,18]. One reason for this might be that mucinous and
non-mucinous cancers were not analyzed separately. Also
differences in antibodies, staining procedures, and analysis of
stainings might have differed from our study. In gallbladder
cancer, REG4 IHC expression has been associated with better
prognosis [22].
Our results show that REG4 IHC expression is a marker of
favorable prognosis in non-mucinous CRC, whereas no difference
emerged in mucinous CRC. REG4 expression is constitutively
high in mucinous tumors (i.e. Pseudomyxoma peritonei, and
mucinous cystadenomas and mucocellular gastric cancer) This
may explain why no clear variation in REG4 expression was found
by IHC in the group of mucinous CRC tumours. Differences in
REG4 expression was on the other hand apparent in non-
mucinous CRC. In our patients under 65, elevated REG4 was an
Figure 2. REG4 expression in primary tumors and lymph-node
metastases. REG4-negative expression in tumor and -positive in
adjacent epithelium (A). Positive REG4 expression in primary tumor (B)
and negative in its corresponding lymph node metastasis (C).Positive
REG4 expression in primary tumor (D) and positive in its corresponding
lymph node metastasis (E). Original magnification x 4 in figure A and x
20 in B–E.
doi:10.1371/journal.pone.0109600.g002
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independent factor for better prognosis in non-mucinous CRC. It
thus seems plausible that REG4 mRNA levels may be elevated in
CRC patients with poor prognosis, but this is not translated to
protein. Further studies are thus warranted to compare REG4
mRNA levels with REG4 IHC case by case.
Our results regarding five pairs of REG4-positive primary
tumors and their corresponding lymph-node metastases showed
that of five lymph nodes, only two showed REG4 expression; this
may imply that a REG4-negative subpopulation of tumor cells is
more likely to metastasize than REG4-positive cells.
REG4, is expressed in inflammatory bowel diseases and also in
the margins of peptic ulcers, is considered a marker of
inflammation [6]. In some of our whole-tissue sections tumor
tissue stained negative for REG4, but the adjacent benign
epithelium expressed REG4 strongly, apparently representing an
inflammatory reaction against the tumor.
It is noteworthy that REG4 expression confers a more favorable
prognosis only in CRC without mucinous differentiation. In fact,
high expression of REG4 has appeared in aggressive forms of
gastrointestinal cancer that show mucinous phenotype-like muco-
cellular (signet ring cell) carcinoma of the stomach [9]. On the
other hand, REG4 is also abundantly present in mucin-rich
cystadenomas of the appendix and in its malignant, disseminated
form, pseudomyxoma peritonei, which is notoriously therapy
resistant.
A majority of entero-endocrine cells in normal intestinal mucosa
display high physiological expression of REG4 with co-expression
of synaptophysin and chromogranin. Intestinal neuro-endocrine
tumors of both low and high grade also show REG4 positivity,
frequently with a peculiar anatomical distribution with the
strongest expression in a single layer of cells in the periphery of
the tumor that are in intimate contact with the surrounding stroma
[6] Given this, it was somewhat intriguing that synaptophysin- and
chromogranin-positive CRC tumors in this study remained
negative for REG4.
Several reports suggest the oncogenic role of REG4 in the
development of cancer in the gastrointestinal tract. The ultimate
molecular mechanisms have, however, remained elusive. Bishnu-
pari et al [24] reported that treatment of cultured colon
adenocarcinoma cells with recombinant REG4 protein induced
phosphorylation of the EGF receptor and Akt. They suggested
that REG4 is a transactivator of the EGFR/Akt signaling
pathway. A further elucidation of the role of exogenous REG4
as a regulator of cell growth potential is, however, awaiting
Table 2. Association between REG4 expression and clinicopathologic parameters in colorectal cancer.
REG4 expression
negative positive
n (%) 580 (73.1) 213 (28.9) p-value
Age. years
,65 245 (42.2) 94 (44.1) 0.686
$65 335 (57.8) 119 (55.9)
Gender
Male 313 (54.0) 128 (60.1) 0.124
Female 267 (46.0) 85 (39.9)
Dukes
A 75 (12.9) 44 (20.7) 0.014
B 202 (34.8) 73 (34.3)
C 164 (28.3) 55 (25.8)
D 139 (24.0) 41 (19.2)
Grade (WHO)
1 14 (2.4) 13 (6.2) 0.064
2 394 (68.3) 150 (71.1)
3 150 (26.0) 38 (18.0)
4 19 (3.3) 10 (4.7)
Missing
Location
Colon 294 (50.7) 116 (54.5) 0.346
Rectum 286 (49.3) 97 (45.5)
Side
Right 147 (25.3) 70 (32.9) 0.035
Left 433 (74.7) 143 (67.1)
Histology
Adenomatous 539 (92.9) 173 (81.6) ,0.0001
Mucinous 41 (7.1) 39 (18.4)
Exact Pearson chi-square test for 262 tables and exact linear-by-linear association test for tables with ordered variables. Missing data excluded from analyses.
doi:10.1371/journal.pone.0109600.t002
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identification of the putative REG4 receptor. No evidence shows
that increased expression of REG4 by itself induces cancerous
growth, however. Our observations on mice transgenic for human
REG4 cDNA under the villin promoter that leads to global
overexpression of REG4 in the intestinal mucosa did not induce
increased tumor formation or mucosal hyperplasia (unpublished
data).
Regulation of REG4 expression is still poorly understood. We
originally reported strongly up-regulated expression of REG4 also
in inflamed IBD mucosa of IBD-like foci of gastritis-induced
intestinal metaplasia in the stomach [6]. This suggests that
inflammatory cytokines may influence REG4 expression. Neuro-
endocrine differentiation, on the other hand, as seen in
enteroendocrine cells, appears to confer constitutive expression
of REG4. We recently reported co-expression of REG4 with the
neuronal transcription factor Hath-1 (atonal, Math-1) in neuro-
endocrine tumors [9]. What remains to be established is whether
one regulator of REG4 expression is Hath-1.
Compared to whole tissue sections, the TMA technique allows
analysis of larger patient cohorts, but with a smaller proportion of
the tumors evaluated. This posed no problem here, however, as
the REG4 staining pattern in our whole section staining was
homogenous. For technical reasons, up to 5% of the specimens
were lost in the TMA-production and -staining process. The
strength of this study is a large, well-characterized CRC-patient
cohort with our long follow-up time.
Here we show, to our knowledge for the first time, that REG4
IHC expression is an independent marker of favorable prognosis
in non-mucinous colorectal cancer in patients under 65. These
results are in disagreement with those obtained by evaluating
mRNA levels; our discrepancies with others’ findings warrant
further studies.
Supporting Information
Figure S1 Clinicopathologic characteristics of the study popu-
lation and subgroup population.
(DOCX)
Figure S2 REG4 expression indicating better prognosis in non-
mucinous colorectal cancer for younger patients. Disease-specific
survival analysis according to the Kaplan-Meier method for REG4
expression in non-mucinous colorectal cancer in patients under 65
by the log-rank test.
(TIFF)
Figure S3 REG4 expression showing no difference in survival in
non-mucinous colorectal cancer for older patients. Disease-specific
survival analysis according to the Kaplan-Meier method for REG4
expression in non-mucinous colorectal cancer in patients 65 and
older by the log-rank test.
(TIFF)
Table 3. Association between REG4 expression and clinicopathologic parameters in non-mucinous colorectal cancer.
REG4 expression
negative positive
n (%) 539 173 p-value
Age. years
,65 228 (42.3) 76 (43.9) 0.706
$65 311 (57.7) 97 (56.1)
Gender
Male 289 (53.6) 101 (58.4) 0.273
Female 250 (46.4) 72 (41.6)
Dukes
A 74 (13.7) 39 (22.5) 0.005
B 186 (34.5) 59 (34.1)
C 148 (27.5) 46 (26.6)
D 131 (24.3) 29 (16.8)
Grade (WHO)
1 13 (2.4) 11 (6.4) 0.023
2 375 (70.0) 124 (72.5)
3 132 (24.6) 32 (18.7)
4 16 (3.0) 4 (2.3)
Missing
Location
Colon 268 (49.7) 87 (50.3) 0.897
Rectum 271 (50.3) 86 (49.7)
Side
Right 126 (23.4) 49 (28.3) 0.189
Left 413 (76.6) 124 (71.7)
Exact Pearson chi-square test for 262 tables and exact linear-by-linear association test for tables with ordered variables. Missing data excluded from analyses.
doi:10.1371/journal.pone.0109600.t003
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Table 4. Association of REG4 expression with other biomarkers in colorectal cancer and non-mucinous colorectal cancer.
REG4 expression
Colorectal cancer Non-mucinous colorectal cancer
negative positive negative positive
n (%) 162 (76.4) 50 (23.6) p-value 157 (78.5) 43 (21.5) p-value
MUC1 expression
low 131 (84.0) 36 (78.3) 0.368 127 (84.1) 31 (79.5) 0.492
high 25 (16.0) 10 (21.7) 24 (15.9) 8 (20.5)
MUC2 expression
low 147 (93.6) 24 (48.0) ,0.0001 143 (94.1) 22 (51.2) ,0.0001
high 10 (6.4) 26 (52.0) 9 (5.9) 21 (48.8)
MUC4 expression
neg 90 (57.0) 14 (29.2) 0.001 88 (57.5) 13 (31.7) 0.003
pos 68 (43.0) 34 (70.8) 65 (42.5) 28 (68.3)
MUC5AC expression
neg 150 (96.2) 38 (82.6) 0.004 147 (97.4) 31 (79.5) ,0.0001
pos 6 (3.8) 8 (17.4) 4 (2.6) 8 (20.5)
Neuroendocrine differentiation
Negative 152 (93.8) 45 (90.0) 0.354 147 (93.6) 38 (88.4) 0.323
Positive 10 (6.2) 5 (10.0) 10 (6.4) 5 (11.6)
Exact pearson chi-square test for 262 tables. Missing data excluded from analyses.
doi:10.1371/journal.pone.0109600.t004
Figure 3. REG4 expression indicating better prognosis in non-mucinous colorectal cancer. Disease-specific survival analysis according to
the Kaplan-Meier method for REG4 expression in non-mucinous colorectal cancer by the log-rank test.
doi:10.1371/journal.pone.0109600.g003
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Table 5. Cox uni-and multivariable analysis of relative risk of death from non-mucinous colorectal cancer within 5 years by REG4
expression for patients under 65.
REG4 expression HR (95% CI) P-value
N




Negative 1.00 228 (83) 1.00 227 (83)
Positive 0.57 (0.34–0.94) 0.029 76 (18) 0.55 (0.33–0.92) 0.022 76 (18)
Abbreviations: CI = confidence interval, HR =hazard ratio. Multivariable analysis included adjustment for gender, Dukes class, differentiation grade (G1/2 vs G3/4).
doi:10.1371/journal.pone.0109600.t005
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